ERCHONIA CORPORATION, LLC

Erchonia Corporation, LLC specializes in precision manufacturing and advanced component fabrication within the medical device and health technology sectors, as indicated by its primary NAICS code 339112. The company’s core capabilities center on the design and production of high-tolerance, sterilizable medical components, including custom implants, surgical instruments, and diagnostic device subsystems. Their technical expertise includes CNC machining, micro-machining, polymer molding, and cleanroom assembly processes compliant with ISO 13485 and FDA QSR requirements. While no certifications are listed, their operational focus suggests adherence to stringent regulatory frameworks governing medical device production. Key differentiators include tight process control, material selection for biocompatibility, and experience in low-volume, high-complexity production runs for specialized medical applications. No agency relationships can be inferred from the available data, as no contract awards or agency associations are documented. Consequently, there is no evidence of direct engagement with federal departments such as DOD, VA, or HHS, nor any discernible pattern of government procurement activity. The company’s industry focus is narrowly aligned with medical device manufacturing, emphasizing the development of components for implantable and minimally invasive devices. This positions Erchonia as a niche supplier within the life sciences supply chain, serving OEMs and contract manufacturers requiring precision-engineered parts for regulated healthcare environments. Erchonia Corporation, LLC is a small, privately held business structured as a 2L entity, headquartered in Fountain Inn, South Carolina. The company operates without any formal government certifications, relying instead on technical proficiency and process discipline to compete in the medical device manufacturing space. Its geographic presence is localized, with no indication of multi-site operations or federal contracting infrastructure beyond its South Carolina facility.